Steward Partners Investment Advisory LLC Has $434,000 Position in Haleon plc (NYSE:HLN)

Steward Partners Investment Advisory LLC raised its stake in Haleon plc (NYSE:HLN - Free Report) by 198.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,523 shares of the company's stock after acquiring an additional 30,276 shares during the period. Steward Partners Investment Advisory LLC's holdings in Haleon were worth $434,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Sierra Ocean LLC acquired a new position in shares of Haleon during the fourth quarter worth approximately $26,000. Versant Capital Management Inc boosted its position in shares of Haleon by 2,029.1% during the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock worth $34,000 after buying an additional 3,348 shares during the period. Geneos Wealth Management Inc. acquired a new position in shares of Haleon during the fourth quarter worth approximately $35,000. Toronto Dominion Bank boosted its position in shares of Haleon by 3,470.0% during the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock worth $38,000 after buying an additional 3,470 shares during the period. Finally, Spire Wealth Management acquired a new position in shares of Haleon during the fourth quarter worth approximately $39,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Price Performance

Shares of NYSE HLN traded down $0.04 during trading on Friday, hitting $10.16. The company had a trading volume of 8,127,571 shares, compared to its average volume of 6,640,348. The company has a market cap of $45.97 billion, a P/E ratio of 29.87, a PEG ratio of 2.82 and a beta of 0.25. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The business's 50-day moving average is $9.75 and its 200 day moving average is $9.87. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Remove Ads

Haleon (NYSE:HLN - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. Equities research analysts predict that Haleon plc will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently declared a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be issued a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This represents a dividend yield of 1.6%. This is a boost from Haleon's previous -- dividend of $0.05. Haleon's dividend payout ratio is currently 58.97%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Hsbc Global Res cut Haleon from a "strong-buy" rating to a "hold" rating in a report on Wednesday, March 5th. HSBC reissued a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Sanford C. Bernstein cut Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Finally, Morgan Stanley cut Haleon from an "overweight" rating to an "equal weight" rating in a report on Friday, January 10th. Six research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.